Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain mapping breakthrough could revolutionize epilepsy surgery

NCT ID NCT04649008

First seen Feb 16, 2026 · Last updated Jun 23, 2026 · Updated 14 times

Summary

This study combines advanced MRI scans with intracranial EEG recordings to map brain networks in people with drug-resistant epilepsy. Researchers aim to develop noninvasive imaging biomarkers that predict where seizures start and how they spread. The goal is to improve surgical outcomes and pave the way for more personalized, less invasive treatments. The study is recruiting 290 participants at the University of Pennsylvania.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to better, less invasive ways to pinpoint seizure origins and improve epilepsy surgery success.

What could go wrong

This is an early-phase observational study, so it may not directly lead to new treatments. Results may not apply to all epilepsy patients.

Conditions

The condition(s) this trial relates to.

Drug Resistant Epilepsy epilepsy temporal lobe epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.